Ariad Pharmaceuticals (ARIA) : Js Capital Management scooped up 238,700 additional shares in Ariad Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 868,700 shares of Ariad Pharmaceuticals which is valued at $9,190,846.Ariad Pharmaceuticals makes up approximately 5.22% of Js Capital Management’s portfolio.
Other Hedge Funds, Including , Walleye Trading added ARIA to its portfolio by purchasing 500 company shares during the most recent quarter which is valued at $5,290.Parametric Portfolio Associates boosted its stake in ARIA in the latest quarter, The investment management firm added 6,155 additional shares and now holds a total of 73,249 shares of Ariad Pharmaceuticals which is valued at $774,974.Vanguard Group Inc boosted its stake in ARIA in the latest quarter, The investment management firm added 259,003 additional shares and now holds a total of 12,724,399 shares of Ariad Pharmaceuticals which is valued at $134,624,141. Ariad Pharmaceuticals makes up approx 0.01% of Vanguard Group Inc’s portfolio. Tower Research Capital (trc) sold out all of its stake in ARIA during the most recent quarter. The investment firm sold 2,916 shares of ARIA which is valued $30,851. Hanseatic Management Services Inc added ARIA to its portfolio by purchasing 96 company shares during the most recent quarter which is valued at $975.
Ariad Pharmaceuticals closed down -0.15 points or -1.45% at $10.19 with 25,49,575 shares getting traded on Thursday. Post opening the session at $10.33, the shares hit an intraday low of $10.06 and an intraday high of $10.37 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Ariad Pharmaceuticals reported $0.59 EPS for the quarter, beating the analyst consensus estimate by $ 0.70 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $-0.11. The company had revenue of $68.13 million for the quarter, compared to analysts expectations of $62.11 million. The company’s revenue was up 133.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.28 EPS.
ARIAD Pharmaceuticals Inc. is a global oncology company. The Company is engaged in the discovery development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib) brigatinib (AP26113) AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI) which is approved in the United States Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788 is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).